Last reviewed · How we verify
Belladonna and Opium Suppository
At a glance
| Generic name | Belladonna and Opium Suppository |
|---|---|
| Sponsor | Campbell Grant |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The Use of Belladonna and Opium Suppository in the Treatment of Postoperative Stent Pain (PHASE4)
- Effects of Perioperative B&O Suppositories on Post-op Pain and Morphine Use After Laparoscopic Prostatectomy (NA)
- B&O for TLH Post-operative Pain and Nausea (PHASE4)
- Timing of B and O Suppositories to Help Relieve Post-operative Bladder Spasms (PHASE4)
- Assessing Maternal Post-partum Pain With Suppositories (PHASE4)
- Effect of an Anti-spasmodic Suppository to Improve Comfort After Urologic Surgery (NA)
- Postoperative Belladonna and Morphine Suppositories in Vaginal Surgery (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Belladonna and Opium Suppository CI brief — competitive landscape report
- Belladonna and Opium Suppository updates RSS · CI watch RSS
- Campbell Grant portfolio CI